Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12005MR)

This product GTTS-WQ12005MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12005MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9539MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ7811MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ13078MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ450MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 3G3
GTTS-WQ9684MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ12075MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ8859MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ13623MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA R4930
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW